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Abstract
Background: Coronavirus Disease-2019 (COVID-19) pandemic has become a major health event that endangers
people health throughout China and the world. Understanding the factors associated with COVID-19 disease
severity could support the early identification of patients with high risk for disease progression, inform prevention
and control activities, and potentially reduce mortality. This study aims to describe the characteristics of patients
with COVID-19 and factors associated with severe or critically ill presentation in Jiangsu province, China.
Methods: Multicentre retrospective cohort study of all individuals with confirmed Severe Acute Respiratory
Syndrome Coronavirus-2 (SARS-CoV-2) infections diagnosed at 24 COVID-19-designated hospitals in Jiangsu
province between the 10th January and 15th March 2020. Demographic, clinical, laboratory, and radiological data
were collected at hospital admission and data on disease severity were collected during follow-up. Patients were
categorised as asymptomatic/mild/moderate, and severe/critically ill according to the worst level of COVID-19
recorded during hospitalisation.
Results: A total of 625 patients, 64 (10.2%) were severe/critically ill and 561 (89.8%) were asymptomatic/mild/
moderate. All patients were discharged and no patients died. Patients with severe/critically ill COVID-19 were more
likely to be older, to be single onset (i.e. not belong to a cluster of cases in a family/community, etc.), to have a
medical history of hypertension and diabetes; had higher temperature, faster respiratory rates, lower peripheral
capillary oxygen saturation (SpO2), and higher computer tomography (CT) image quadrant scores and pulmonary
opacity percentage; had increased C-reactive protein, fibrinogen, and D-dimer on admission; and had lower white
blood cells, lymphocyte, and platelet counts and albumin on admission than asymptomatic/mild/moderate cases.
Multivariable regression showed that odds of being a severe/critically ill case were associated with age (year) (OR
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1.06, 95%CI 1.03–1.09), lymphocyte count (109/L) (OR 0.25, 95%CI 0.08–0.74), and pulmonary opacity in CT (per 5%)
on admission (OR 1.31, 95%CI 1.15–1.51).
Conclusions: Severe or critically ill patients with COVID-19 is about one-tenths of patients in Jiangsu. Age,
lymphocyte count, and pulmonary opacity in CT on admission were associated with risk of severe or critically ill
COVID-19.
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Highlights
 About one-tenths of patients with COVID-19 in
Jiangsu had severe or critically ill presentation
 All patients were discharged and no patients died by
the end of study
 Risk of severe or critically ill COVID-19 patients in-
creased with age
 Low lymphocyte count and high pulmonary opacity
score in CT on admission were associated with high
risk of severe or critically ill COVID-19
Background
Coronavirus Disease 2019 (COVID-19), caused by the
etiological agent Severe Acute Respiratory Syndrome
Coronavirus-2 (SARS-CoV-2), was first reported from
Wuhan, Hubei province, China, in December 2019. The
World Health Organization (WHO) declared a pan-
demic the 11th March 2020 [1]. The COVID-19 pan-
demic have spread quickly from a focal outbreak to over
7410, 000 cases with more than 400, 000 deaths affecting
more than 140 countries by the 12th June 2020 [2].
China had reported over 80, 000 confirmed cases by
the 13th March 2020 [2]. Although the original epicentre
was located in Wuhan, other provinces became affected
in the following weeks. In a case series of the first 44,672
confirmed cases, 1023 patients had died, with a crude
case fatality rate (CFR) of 2.3%, and mortality was higher
among critically ill patients, who had a CFR of 49% [3].
In Hubei, the proportion of health workers with severe
or critical ill COVID-19 was higher than in other prov-
inces (10.4 and 7.0%, respectively) [3]. Compared to
China, the crude CFR in South Korea is lower among
both males (1.1%) and females (0.4%) [4], and the crude
CFR in Australia (1.4%) [5] and in countries of the Euro-
pean Union (EU) and European Economic Area (EEA)
was also lower (1.5%) [6], while the crude CFR in Italy
was much higher (7.2%) [7].
COVID-19 initial symptoms are not specific, present-
ing with fever, and cough, which can then resolve spon-
taneously or progress to shortness of breath, dyspnoea,
and pneumonia, leading to acute respiratory distress
syndrome (ARDS), renal failure, coagulation dysfunction,
multiple organ failure and death [8–13]. Demographic
features (eg age and gender); epidemiological features
(eg smoking and comorbidities); laboratory parameters
(eg C-reactive protein, albumin, cytokine, lactate de-
hydrogenase, D-dimer, platelet, lymphocyte, and neutro-
phil); clinical manifestations (eg cough, expectoration,
chest pain, and dyspnea); computer tomography (CT)
image test results; and others, have been reported to be as-
sociated with the severity of COVID-19 in some small
studies in China [14–20], and other countires [13, 21, 22].
Understanding the factors associated with COVID-19
disease severity could support the early identification of
patients with high risk for severe/critically ill COVID-19
presentation and inform prevention and control activ-
ities and reduce mortality. Hubei was the COVID-19
epicentre of China at the time of data collection for this
study (from the 10th January 2020 to the 15th March
2020), so patients in other parts of China, outside Hubei,
may have different profiles of demographic, epidemio-
logical, clinical characteristics, laboratory parameters,
and image test results. Knowing those profiles may help
predict the severity of COVID-19.
Jiangsu, a province in China over 600 km from Hubei
without common geographical borders and 80 million
population, reported over 600 patients infected with
COVID-19. We report here an analysis of nearly all
cases in Jiangsu province from the 10th January 2020 to
the 15th March 2020 to describe the demographic, epi-
demiological, clinical, laboratory, and imaging character-
istics of cases and to identify risk factors for severe/
critically ill COVID-19 presentation. Previous studies
were mostly small and descriptive in nature. Our study
will use data from the whole Jiangsu province and make
inferential statistical analyses by means of multivariate
regression model to control for possible confounding
factors and identify independent risk factors of becom-
ing a severe/critically ill case.
Methods
Study design and population
This is a multicentre retrospective cohort study. All pa-
tients were included if they (1) were clinically diagnosed
and then confirmed to have COVID-19 in Jiangsu prov-
ince from the 10th January 2020 up to the 15th March
2020, and (2) fulfilled the diagnostic criteria for the
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“Diagnosis and Treatment Protocol for Novel Corona-
virus Pneumonia (Trial Version 7)” released by National
Health Commission & National Administration of Trad-
itional Chinese Medicine of China [23]. The diagnosis of
COVID-19 was based on epidemiological history, clinical
manifestations, imaging manifestations of pneumonia in
CT scans, and laboratory confirmation [23, 24]. Patients
without medical records were excluded.
The Ethics Committee of Zhongda Hospital, Affiliated
to Southeast University, approved the study protocols
(2020ZDSYLL013–P01 and 2020ZDSYLL019–P01). Pa-
tient informed consent was waived due to the retro-
spective study design.
Data measures
The primary outcome was severe or critically ill within
the follow up period. Patients were categorised by dis-
ease severity into (1) asymptomatic or mild, or moder-
ate, and (2) severe or critically ill, according to
“Diagnosis and Treatment Protocol for Novel Corona-
virus Pneumonia (Trial Version 7)” [23]. Asymptomatic
infections were defined as the absence of clinical symp-
toms with a positive nucleic acid test (real-time reverse
transcriptase–polymerase chain reaction assay, RT-PCR,
for SARS-CoV-2). Mild COVID-19 disease was defined
as the presence of mild clinical symptoms without re-
spiratory distress and the absence of imaging manifesta-
tions of pneumonia. Moderate disease was defined as
the presence of fever, with respiratory symptoms and an
image of pneumonia in CT scans. Severe disease was de-
fined as the presence of at least one of the three condi-
tions: respiratory distress, a respiratory rate ≥ 30 beats /
min; oxygen saturation in resting state ≤93%; or an ar-
terial blood oxygen partial pressure / oxygen concentra-
tion ≤ 300 mmHg (1 mmHg = 0.133 kPa). Critically ill
was defined as having respiratory failure requiring mech-
anical ventilation, shock or combined organ failure re-
quiring intensive care unit (ICU) monitoring and
treatment. A clustering onset was defined as the occur-
rence of two or more confirmed COVID-19 cases in the
same cluster/group within 14 days, such as family, com-
munity, hospital, working place or public place, etc. A
clustering onset could occur due to interpersonal trans-
mission via close contact with or joint exposure to a
confirmed COVID-19 case. Others cases not meeting
the conditions of the clustering onset were classified as a
single onset. All patients were followed up to the 15th
March 2020.
Data were collected using case record forms and elec-
tronic medical record systems and included demo-
graphic, epidemiological, clinical, laboratory, and
imaging information provided by the Data Center of
Jiangsu Provincial Health Commission without any pa-
tient’s personal information. The day of admission to a
COVID-19-designated hospital was considered the first
day of hospitalisation. The severity of illness was
assessed by two physicians. Severity was assessed at days
1, 2, 3, 4, 5, 6, 7 and 14 after admission and patients
were followed for up to discharge. ICU admissions were
recorded. Imaging grading was performed by two inde-
pendent radiologists with more than 5 years’ experience
in pulmonary imaging. Chest CT axial sections were di-
vided into quadrants (left and right, anterior and poster-
ior) by drawing horizontal and vertical lines through the
centre of the chest. Quadrant scores were estimated as
the sum of quadrants with pulmonary opacities extend-
ing from the proximal to the distal end of the chest and
ranged from 0 to 4. Pulmonary opacity was visually esti-
mated and assigned a percentage of pulmonary opacity
area in the area of bilateral lungs, rounded to the nearest
5%.
Statistical analysis
Variables
Primary outcome variable was the occurrence of severe/
critically ill case. Predictive variables included sex, age,
exposure type, types of disease onset, initial symptoms,
medical history, vital signs (including body temperature,
heart rate (HR), respiratory rate, and peripheral capillary
oxygen saturation (SpO2)), CT image parameters (in-
cluding quadrant score and pulmonary opacity), and la-
boratory parameters (including white blood cells count,
neutrophil, lymphocyte, platelet, albumin, creatinine, C-
reactive protein, activated partial thromboplastin time,
fibrinogen, and D-dimer). Those variables were mea-
sured at hospital admission. The other variables includ-
ing supportive treatments and medical drugs were
collected during the follow-up period.
Statistical analysis
Continuous variables were described using means
(standard deviations, SD) or medians (with inter-quartile
range, IQR) by disease severity and were compared using
ANOVA or Kruskal-Wallis tests as appropriate. Categor-
ical variables were summarised using frequencies and
percentages and compared using Fisher exact tests.
Logistic regression models were used to identify the
risk factors for having a severe or critically ill status.
Analysis was performed in 2 steps. Firstly, a univariate
logistic regression model was fitted for each variable
based on completed cases. As there are many potential
predictors, we chose the variables for univariate regres-
sion analysis if a variable is significant at 5%. Respiratory
rate and SpO2 were not included in the regression ana-
lyses since they were part of criterion for classifying the
disease severity. All variables selected for univariate re-
gression analysis were also included in the second stage
of the multivariate logistic regression. Missing covariates
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at admission were imputed with multiple imputation
using a Markov Chain Monte Carlo simulation method
with 10 iterations. In the logistic regression analysis,
odds ratios (ORs) for having a severe or critically ill sta-
tus for each variable were calculated along with 95%
confidence intervals (CIs). A sensitivity analysis was per-
formed on the completed cases. The 2-tailed P < 0.05
was considered as statistically significant for all analyses.
The analyses were performed using SAS 9.4 (SAS
Institute).
Results
From the 10th January 2020 to 15th March 2020, 721
suspected cases with possible COVID-19 were admitted
in 24 hospitals in Jiangsu province, China, while 90 cases
were excluded because of negative reverse transcriptase–
polymerase chain reaction assay. Six hundred thirty-one
cases were diagnosed with COVID-19 totally. Of these,
625 (99.0%) had retrievable medical records and were in-
cluded in the analysis (Fig. 1).
Table 1 describes the characteristics of patients at the
time of admission by disease severity and Table S1 pro-
vides a more detailed description of the five severity cat-
egories. 561 (89.8%) patients were asymptomatic/mild/
moderate and 64 (10.2%) patients were severe or critic-
ally ill. Patients with severe/critically ill COVID-19 were
more likely to be older and to be single onset (i.e. not
belong to a cluster of cases in a family/community, etc.).
Patients with severe/critically ill presentation were more
likely to have a medical history of hypertension and dia-
betes. Patients with severe/critically ill COVID-19 on ad-
mission had higher temperature, faster respiratory rates,
lower SpO2, and higher CT image quadrant scores and
pulmonary opacity percentage (Table 1 and Table S1).
Cases with severe/critically ill presentation were more
likely to have increased C-reactive protein, fibrinogen,
and D-dimer than asymptomatic/mild/moderate cases.
Similarly, severe/critically ill cases had lower white blood
cells, lymphocyte, and platelet counts and albumin
(Table 1). As expected, severe cases were more likely to
use supportive treatments and medical drugs, including
antibiotics and antivirals, except interferon (Table 2).
None of the patients died and 625 (100%) of 625 pa-
tients were discharged by the end of study (15th March
2020). The results from the univariate and multivariate
logistic regression analyses are presented in Table 3.
Factors independently associated with severe or critically
ill infection included age (year) (OR 1.06, 95%CI 1.03–
1.09), lymphocyte count (109/L) (OR 0.25, 95%CI 0.08–
0.74), and pulmonary opacity in CT (per 5%) on admis-
sion (OR 1.31, 95%CI 1.15–1.51). Sensitivity analysis
showed that they remained statistically significant in a
logistic model with only above three variables based on
the completed cases without missing data.
Discussion
In this large multicentre cohort, 64 (10.2%) of 625 pa-
tients were severe or critically ill. This proportion of se-
vere or critically ill cases is lower than the 17.7%
reported from Wuhan but similar to the 10.4% in Hubei
province and higher than the 7.0% reported for areas
outside Hubei province [3]. Specifically, it is lower
than the figures reported from several case series from
Wuhan including 13 (32%) ICU admission among 41
cases with 6 (15%) deaths [25]; 11 (11%) deaths among
99 cases [9]; and 36 (26.1%) ICU admissions among 138
patients, with 6 deaths (4.3%) [10]. The lower proportion
than that in Hubei is likely due to several factors, includ-
ing more adequate medical resources, better disease
721 suspected cases with possible COVID-19 were admitted in 24 
hospitals in Jiangsu province from January 10, 2020 to March 15, 2020
631 cases with confirmed COVID-19 
90 cases excluded because real-time reverse 
transcriptase–polymerase chain reaction assays 
showed negative
625 COVID-19 cases included in the analysis 
6 cases excluded due to missing medical records 
Fig. 1 Study flow diagram
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Table 1 Demographic and clinical characteristics of patients with COVID-19 at admissiona
Severe/Critically ill
Category Characteristics Yes (N = 64) No (N = 561) All (N = 625) P-value
Demographic, n/N (%), N, mean (SD)
Male 41/64(64.1%) 288/561(51.3%) 329/625(52.6%) 0.0534
Female 23/64(35.9%) 273/561(48.7%) 296/625(47.4%)
Age (year) 64,59.53(13.43) 561,42.72(16.73) 625,44.44(17.19) <.0001
≤18 years 0/64(0.0%) 37/561(6.6%) 37/625(5.9%) <.0001
19–44 years 6/64(9.4%) 255/561(45.5%) 261/625(41.8%)
45–64 years 32/64(50.0%) 216/561(38.5%) 248/625(39.7%)
65+ years 26/64(40.6%) 53/561(9.4%) 79/625(12.6%)
Exposure type, n/N (%)
Imported cases 25/64(39.1%) 194/561(34.6%) 219/625(35.0%) 0.4765
Local cases 39/64(60.9%) 367/561(65.4%) 406/625(65.0%)
Types of disease onset, n/N (%)
Single onset 40/64(62.5%) 270/561(48.1%) 310/625(49.6%) 0.0294
Clustering onset 24/64(37.5%) 291/561(51.9%) 315/625(50.4%)
Initial symptoms, n/N (%)
Fever 52/64(81.3%) 360/561(64.2%) 412/625(65.9%) 0.0063
Cough 44/64(68.8%) 300/561(53.5%) 344/625(55.0%) 0.0200
Sputum 25/64(39.1%) 141/561(25.1%) 166/625(26.6%) 0.0168
Medical history, n/N (%)
Hypertension 19/64(29.7%) 72/561(12.8%) 91/625(14.6%) 0.0003
Diabetes 10/64(15.6%) 30/561(5.3%) 40/625(6.4%) 0.0015
Stroke 2/64(3.1%) 8/560(1.4%) 10/624(1.6%) 0.2736
Vital signs, N, mean (SD)
Temperature (°C) 64,37.30(0.94) 561,37.02(0.70) 625,37.05(0.73) 0.0040
HR (bpm) 64,89.98(15.06) 561,86.84(13.25) 625,87.17(13.46) 0.0772
Respiratory rate (breath per min) 64,20.98(4.87) 561,18.87(2.04) 625,19.08(2.56) <.0001
SpO2 (%) 64,95.53(4.70) 561,97.92(1.15) 625,97.68(1.99) <.0001
CT image, N, median (IQR)
Quadrant score (1–4) 58,4.0(4.0–4.0) 438,2.0(1.0–4.0) 496,2.0(1.0–4.0) <.0001
Pulmonary opacity (%) 58,50.0(35.0–70.0) 438,20.0(5.0–30.0) 496,20.0(5.0–40.0) <.0001
Laboratory test, N, median (IQR)
WBC Count (109/L) 52,4.3(3.4–5.8) 461,5.0(4.0–6.3) 513,4.9(3.9–6.2) 0.0440
Neutrophil (109/L) 52,2.9(2.0–4.4) 455,3.0(2.2–4.0) 507,3.0(2.2–4.0) 0.7435
Lymphocyte (109/L) 52,0.7(0.5–1.0) 453,1.4(1.0–1.8) 505,1.3(0.9–1.7) <.0001
Platelet (109/L) 48,154.0(118.0–185.0) 446,188.5(154.0–222.0) 494,183.5(151.0–219.0) <.0001
Albumin (g/L) 48,39.7(34.2–41.4) 432,42.0(38.0–45.7) 480,41.4(38.0–45.1) <.0001
Creatinine (umol/L) 49,64.0(51.0–83.0) 427,63.8(51.0–79.0) 476,63.9(51.0–79.0) 0.6950
C-reactive protein (mg/L) 44,40.1(8.6–92.7) 430,10.0(2.6–19.3) 474,10.0(2.7–22.6) <.0001
Activated partial thromboplastin time (s) 54,32.6(28.5–36.5) 459,32.2(27.9–37.4) 513,32.2(28.0–37.2) 0.8158
Fibrinogen (g/L) 53,4.3(3.2–5.9) 443,3.4(2.7–4.1) 496,3.5(2.7–4.2) <.0001
D-dimer (mg/L) 51,0.3(0.2–1.0) 424,0.2(0.1–0.4) 475,0.2(0.1–0.4) 0.0003
aContinuous variables: ANOVA or Kruskal-Wallis tests as appropriate; categorical variables: Fisher exact tests
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Table 2 Clinical management and outcome
n (%) or median (IQR) P-value
Severe/Critically ill
Category Clinical management and outcome Yes (N = 64) No (N = 561) All (N = 625)
Supportive treatments Inotropic and vasoconstrictive agents 5(7.8%) 0(0.0%) 5(0.8%) <.0001
Nasal cannula 53(82.8%) 168(29.9%) 221(35.4%) <.0001
Mask 12(18.8%) 2(0.4%) 14(2.2%) <.0001
High-flow nasal cannula oxygen therapy 24(37.5%) 1(0.2%) 25(4.0%) <.0001
Non-invasive ventilation 34(53.1%) 0(0.0%) 34(5.4%) <.0001
Intermittent mandatory ventilation 5(7.8%) 0(0.0%) 5(0.8%) <.0001
Prone position 17(26.6%) 1(0.2%) 18(2.9%) <.0001
Continuous renal replacement therapy 1(1.6%) 0(0.0%) 1(0.2%) 0.1024
Extracorporeal membrane oxygenation 2(3.1%) 0(0.0%) 2(0.3%) 0.0103
Lung transplantation 2(3.1%) 0(0.0%) 2(0.3%) 0.0103
Medical drugs Traditional Chinese medicine 29(45.3%) 69(12.3%) 98(15.7%) <.0001
Immunoglobulin 50(78.1%) 106(18.9%) 156(25.0%) <.0001
Interferon 47(73.4%) 456(81.3%) 503(80.5%) 0.1363
Antioxidants 35(54.7%) 117(20.9%) 152(24.3%) <.0001
Glucocorticoid 52(81.3%) 90(16.0%) 142(22.7%) <.0001
Thymosin 43(67.2%) 101(18.0%) 144(23.0%) <.0001
Neurotrophic drugs 21(32.8%) 81(14.4%) 102(16.3%) 0.0005
Any antibiotics 59(92.2%) 277(49.4%) 336(53.8%) <.0001
Any antivirals 64(100%) 516(92.0%) 580(92.8%) 0.0098
Clinical outcome Death 0(0.0%) 0(0.0%) 0(0.0%) NC
Hospital stay 21.5(15.0–29.0) 15.0(12.0–21.0) 16.0(12.0–22.0) <.0001
Table 3 Factors associated with severe/critically ill in patients with COVID-19: Results from logistic regression analysis
Univariate analysisa Multivariate analysisb
Variables Odds ratio (95%CI) P-value Odds ratio (95%CI) P-value
Age (year) 1.07(1.05,1.09) <.0001 1.06(1.03,1.09) <.0001
Single onset 1.80(1.05,3.06) 0.0311 0.92(0.43,1.96) 0.8275
Fever 2.42(1.26,4.64) 0.0078 1.50(0.64,3.54) 0.3542
Cough 1.91(1.10,3.33) 0.0216 1.24(0.54,2.87) 0.6110
Sputum 1.91(1.12,3.27) 0.0183 1.12(0.48,2.60) 0.7994
Hypertension 2.87(1.59,5.18) 0.0005 1.06(0.47,2.40) 0.8874
Diabetes 3.28(1.52,7.07) 0.0025 1.64(0.52,5.22) 0.4004
Temperature (°C) 1.59(1.15,2.19) 0.0046 0.95(0.61,1.47) 0.8133
Lymphocyte (109/L) 0.03(0.01,0.08) <.0001 0.25(0.08,0.74) 0.0161
Platelet (109/L) 0.99(0.98,0.99) 0.0003 1.00(0.99,1.00) 0.5147
Albumin (g/L) 0.91(0.87,0.96) 0.0002 0.99(0.92,1.07) 0.8344
C-reactive protein (mg/L) 1.02(1.01,1.02) <.0001 1.00(0.99,1.01) 0.9789
Fibrinogen (g/L) 1.87(1.50,2.32) <.0001 1.04(0.72,1.49) 0.8327
D-dimer (mg/L) 1.28(1.06,1.55) 0.0088 1.17(0.83,1.66) 0.3625
Quadrant score (1–4) 2.28(1.71,3.05) <.0001 0.90(0.56,1.47) 0.6811
Pulmonary opacity (per 5%) 1.38(1.28,1.49) <.0001 1.31(1.15,1.51) 0.0001
aUnivariate analysis is based on the complete cases without missing value
bMultivariate analysis is based on imputed values for missing data in Lymphocyte, Platelet, Albumin, C-reactive protein, Fibrinogen, D-dimer, Quadrant score and
Pulmonary opacity using multiple imputation method
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recognition and testing capacity, earlier identification of
asymptomatic and mild cases and a more informed sup-
portive care in COVID-19-designated hospitals. The
proportion of critically ill cases in early stage of COVID-
19 outbreak in New York City, USA was much higher
(22% [257]) [26] than in China, with 14.2% treated in the
ICU [27] and 23.6% required mechanical ventilation re-
ported in other studies [28]. Singapore also reported a
higher proportion of severe cases in an early study
(33.3% [6]) [29]. A more recent study from USA re-
ported 5.8% (7162) of cases suffered from severe
COVID-19 [30] which is lower than in China. The pro-
portions of severe COVID-19 in different countries vary
a lot, which may result from quite different study de-
signs, the COVID-19 outbreak stages when data were
collected, population characteristics, health resources,
government response measurements, et al.
Despite this being a hospital-based study, some pa-
tients had no symptoms. This is likely due to testing of
contacts after the identification of an index case and the
policy of hospitalization of all infected individuals at the
initial stages of the epidemic, independently of the pres-
ence of symptoms. This study found that fever, cough,
and sputum were very common among patients with
COVID-19 and more frequent in patients with severe or
critically ill COVID-19. Similar to COVID-19, fever and
cough are the most common symptoms of the other two
diseases caused by coronavirus, i.e. severe acute respira-
tory syndrome (SARS) and Middle East respiratory syn-
drome (MERS) [31, 32]. Fever is a primary symptom for
cytokine storms, with the production of high concentra-
tions of cytokines stimulating abnormally excessive im-
mune responses and inflammation [33–35]. Vital signs
showed severe or critically ill patients had higher body
temperature and respiratory rate, and lower SpO2 on ad-
mission. SpO2 < 90% has been used as a marker for the
use of glucocorticoids during the outbreak [36], and the
oxygenation saturation index is associated with ARDS
severity and increased mortality [37, 38].
Gender had no effect on severity of COVID-19 pa-
tients. Although early reports from Wuhan indicated
more men than women had severe COVID-19, recent
studies reported similar proportions of men and women
admitted to ICUs [9, 11, 25], suggesting gender differ-
ences disappeared with higher incidence. Earlier reports
may have included more males due to a higher occupa-
tional infection risk for males in the markets and con-
gregation places [10].
Our study found that age was independently associ-
ated with severe or critically ill presentation. Age is a
well-established factor for severe/critically ill COVID-19
for individuals > 60, and especially over 80 years old [39,
40]. Similarly, previous reports have indicated patients in
ICUs are older than non-ICU patients [10], and that
CFRs are higher among older individuals [9, 11, 25].
Older patients also have faster disease progression than
younger patients [41], which is similar to the MERS and
SARS presentations, in which, older age (> 60 or 45) is
associated with disease severity (MERS) [42, 43], and
mortality [44, 45]. Older age reflects a greater likelihood
of underlying medical conditions such as hypertension
and diabetes, which predisposes to immunological vul-
nerabilities. Also, age-related immunosenescence may
also contribute to the severe disease [46].
In Wuhan, many asymptomatic patients had abnormal
lung CT findings on admission, which then progressed
to diffuse ground-glass opacities and consolidation [47].
In Jiangsu, several asymptomatic cases also had radio-
logical changes presented as low quadrant scores and
pulmonary opacity scores on admission and severe/crit-
ically-ill cases had higher CT quadrant and pulmonary
opacity scores than moderate cases. Our study also iden-
tified pulmonary opacity as an independent predictor of
severe/critical illness. This is consistent with the previ-
ous study reporting that the CT visual quantitative
evaluation of acute lung inflammatory lesions involving
each lobe in severe or critical cases was significantly
higher than less severe cases [48].
We found severe or critically ill patients had more ob-
vious damage of white blood cells and immune cells
such as lymphocytes with lymphocytes identified as an
independent predictor of more severe disease. COVID-
19 may cause the reduced T lymphocytes, especially
CD4 + T and CD8 + T cells, leading to reduced IFN-γ
production, which may be related to the severity of dis-
ease [49]. In addition, severe or critically ill patients
showed more serious organ dysfunction like reduced al-
bumin on admission which may be a sign of reduced
liver production and increased gastrointestinal or renal
loss, and increased fibrinogen on admission responding
to systemic inflammation and tissue damage, and more
fierce inflammatory response presented as much higher
level of inflammatory markers, such as C-reactive pro-
tein [50–52].
This study has several strengths. Firstly, this is one of
the largest studies describing the clinical characteristics
of patients with COVID-19 and risk factors for severe/
critically ill infection outside the Wuhan, epicentre of
the epidemic in China at the time of data collection for
this study (from the 10th January 2020 to the 15th
March 2020). Secondly, the cohort includes almost all
COVID-19 cases in the province, which may have re-
duced selection bias. Thirdly, Jiangsu province, which is
far from Hubei, provides an opportunity to assess the
demographic, epidemiological, clinical, laboratory, and
imaging features of cases imported from other provinces
and local cases. Fourthly, asymptomatic and mild cases
were included, which provides a more comprehensive
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description of the characteristics of COVID-19 cases
with a broad spectrum of disease severity.
There are also limitations that need mentioning.
Firstly, laboratory and radiological data had a large
amount of missing data preventing their integration in
the analysis. Secondly, the predictive factors identified
may be subject to uncontrolled confounders by un-
known/unmeasured factors such as occupation and
pregnancy. Medical staff and pregnant women may have
different severity profiles. Thirdly, this is a retrospective
observational study and data may be susceptible to
measurement and information bias.
Conclusion
In conclusion, this study demonstrates that patients with
COVID-19 in Jiangsu had a low rate of severe or critic-
ally ill presentation, with no deaths recorded. The
COVID-19 severity is associated with epidemiological
and clinical characteristics, laboratory test, and radio-
logical findings. Age, lymphocyte count, and pulmonary
opacity in CT on admission were independently associ-
ated with risk of severe or critically ill COVID-19
presentation.
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